目的 探討復(fù)方伸筋膠囊聯(lián)合依托考昔治療痛風(fēng)的臨床療效。方法 選取2015年6月-2016年6月在貴陽(yáng)中醫(yī)學(xué)院第二附屬醫(yī)院進(jìn)行治療的痛風(fēng)患者82例，根據(jù)治療方案的差別分為對(duì)照組（41例）和治療組（41例）。對(duì)照組口服依托考昔片，1片/次，1次/d。治療組在對(duì)照組的基礎(chǔ)上口服復(fù)方伸筋膠囊，4粒/次，3次/d。兩組患者均連續(xù)治療7 d。治療后，比較兩組患者的臨床療效，并對(duì)治療前后兩組臨床癥狀評(píng)分、血清炎性因子和血清黃嘌呤氧化酶（XOD）和血尿酸（UA）水平進(jìn)行比較。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為80.49%、95.12%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組患者臨床癥狀評(píng)分均較同組治療前顯著降低（P<0.05），且治療組上述評(píng)分降低的更明顯（P<0.05）；兩組患者血清CRP、IL-1β、IL-6和TNF-α水平均顯著降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組血清炎性因子水平優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組血清XOD、UA水平均較同組治療前顯著降低（P<0.05），且治療組上述指標(biāo)降低的更明顯，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 復(fù)方伸筋膠囊聯(lián)合依托考昔治療痛風(fēng)效果顯著，有利于改善臨床癥狀，明顯降低機(jī)體炎性反應(yīng)和XOD、UA水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical effect of Fufang Shenjin Capsules combined with etoricoxib in treatment of gout. Methods Patients (82 cases) with gout in No. 2 Hospital Affiliated to TCM College of Guiyang from June 2015 to June 2016 were divided into control group (41 cases) and treatment group (41 cases) according to the different treatments. Patients in the control group were po administered with Etoricoxib Tablets, 1 tablets/time, once daily. Patients in the treatment group were po administered with Fufang Shenjin Capsules on the basis of the control group, 4 grains/time, three times daily. The patients in two groups were treated for 7 d. After treatment, the clinical efficacies were evaluated, clinical symptom scores, serum inflammatory factors, XOD and UA levels in serum before and after treatment in two groups were compared. Results After treatment, the total efficacies in the control and treatment groups were 80.49% and 95.12%, respectively, and there were differences between two groups (P<0.05). Clinical symptom scores in two groups were significantly decreased compared with those before treatment in the same group (P<0.05). And the scores in the treatment group were decreased more than those in the control group with significant difference between two groups (P<0.05). CRP, IL-1β, IL-6, and TNF-α levels in serum were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the decreasing degree in the treatment group was obviously better than that in the control group, with significant difference between two groups (P<0.05). XOD and UA levels in serum were significantly decreased (P<0.05). And these indexes in the treatment group were significantly decreased with significant difference between two groups (P<0.05). Conclusion Fufang Shenjin Capsules combined with etoricoxib has clinical curative effect in treatment of gout, and can improve clinical symptoms and significantly reduce the inflammatory reaction and XOD and UA levels, which has a certain clinical application value.